Aptinyx (NASDAQ:APTX) issued its earnings results on Monday. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.52) by $0.16, Bloomberg Earnings reports. The firm had revenue of $0.93 million during the quarter, compared to analyst estimates of $0.95 million. Aptinyx had a negative net margin of 1,166.40% and a negative return on equity of 37.53%.
APTX stock opened at $3.22 on Wednesday. The company has a 50-day moving average price of $3.62. The company has a market capitalization of $118.47 million, a P/E ratio of -1.22 and a beta of -0.03. Aptinyx has a 1-year low of $2.88 and a 1-year high of $32.25.
A number of brokerages have recently issued reports on APTX. Cantor Fitzgerald reissued a “buy” rating on shares of Aptinyx in a research note on Tuesday, April 30th. Svb Leerink began coverage on shares of Aptinyx in a research note on Thursday, June 20th. They set an “outperform” rating and a $12.00 target price for the company. Zacks Investment Research raised shares of Aptinyx from a “hold” rating to a “buy” rating and set a $4.25 target price for the company in a research note on Tuesday, July 16th. JPMorgan Chase & Co. downgraded Aptinyx from a “neutral” rating to an “underweight” rating in a report on Tuesday. Finally, Cowen restated a “buy” rating on shares of Aptinyx in a report on Monday, June 10th. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. Aptinyx presently has a consensus rating of “Buy” and an average price target of $12.71.
Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.
Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.